Research article

A closer look at the spreaders of COVID-19 in Wisconsin and the US

  • Received: 29 January 2021 Accepted: 13 April 2021 Published: 29 April 2021
  • In this study, we design and use a mathematical model to primarily address the question of who are the main drivers of COVID-19 - the symptomatic infectious or the pre-symptomatic and asymptomatic infectious in the state of Wisconsin and the entire United States. To set the stage, we first briefly simulate and illustrate the benefit of lockdown. With these lockdown scenarios, and in general, the more dominant influence of the the pre-symptomatic and asymptomatic infectious over the symptomatic infectious, is shown in various ways. Numerical simulations for the U.S. show that an increase in testing and isolating for the pre-symptomatic and asymptomatic infectious group has up to 4 times more impact than an increase in testing for the symptomatic infectious in terms of cumulative deaths. An increase in testing for the pre-symptomatic and asymptomatic infectious group also has significantly more impact (on the order of twice as much) on reducing the control reproduction number than testing for symptomatic infectious. Lastly, we use our model to simulate an implementation of a natural herd immunity strategy for the entire U.S. and for the state of Wisconsin (once an epicenter for COVID-19). These simulations provide specific examples confirming that such a strategy requires a significant number of deaths before immunity is achieved, and as such, this strategy is certainly questionable in terms of success.

    Citation: Sherry E Scott, Keisha J Cook, Kamal Barley. A closer look at the spreaders of COVID-19 in Wisconsin and the US[J]. Mathematical Biosciences and Engineering, 2021, 18(4): 3733-3754. doi: 10.3934/mbe.2021188

    Related Papers:

    [1] Jie Bai, Xiunan Wang, Jin Wang . An epidemic-economic model for COVID-19. Mathematical Biosciences and Engineering, 2022, 19(9): 9658-9696. doi: 10.3934/mbe.2022449
    [2] Quan-Lin Li, Chengliang Wang, Feifei Yang, Chi Zhang . Markov modeling and performance analysis of infectious diseases with asymptomatic patients. Mathematical Biosciences and Engineering, 2023, 20(10): 17822-17848. doi: 10.3934/mbe.2023792
    [3] Ye Xia . An individual-level probabilistic model and solution for control of infectious diseases. Mathematical Biosciences and Engineering, 2024, 21(10): 7253-7277. doi: 10.3934/mbe.2024320
    [4] Shi Zhao . Estimating the time interval between transmission generations when negative values occur in the serial interval data: using COVID-19 as an example. Mathematical Biosciences and Engineering, 2020, 17(4): 3512-3519. doi: 10.3934/mbe.2020198
    [5] Ayako Suzuki, Hiroshi Nishiura . Transmission dynamics of varicella before, during and after the COVID-19 pandemic in Japan: a modelling study. Mathematical Biosciences and Engineering, 2022, 19(6): 5998-6012. doi: 10.3934/mbe.2022280
    [6] Fen-fen Zhang, Zhen Jin . Effect of travel restrictions, contact tracing and vaccination on control of emerging infectious diseases: transmission of COVID-19 as a case study. Mathematical Biosciences and Engineering, 2022, 19(3): 3177-3201. doi: 10.3934/mbe.2022147
    [7] Zhihua Liu, Pierre Magal, Ousmane Seydi, Glenn Webb . Predicting the cumulative number of cases for the COVID-19 epidemic in China from early data. Mathematical Biosciences and Engineering, 2020, 17(4): 3040-3051. doi: 10.3934/mbe.2020172
    [8] Sarafa A. Iyaniwura, Rabiu Musa, Jude D. Kong . A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20(3): 5379-5412. doi: 10.3934/mbe.2023249
    [9] Haonan Zhong, Wendi Wang . Mathematical analysis for COVID-19 resurgence in the contaminated environment. Mathematical Biosciences and Engineering, 2020, 17(6): 6909-6927. doi: 10.3934/mbe.2020357
    [10] Martin Luther Mann Manyombe, Joseph Mbang, Jean Lubuma, Berge Tsanou . Global dynamics of a vaccination model for infectious diseases with asymptomatic carriers. Mathematical Biosciences and Engineering, 2016, 13(4): 813-840. doi: 10.3934/mbe.2016019
  • In this study, we design and use a mathematical model to primarily address the question of who are the main drivers of COVID-19 - the symptomatic infectious or the pre-symptomatic and asymptomatic infectious in the state of Wisconsin and the entire United States. To set the stage, we first briefly simulate and illustrate the benefit of lockdown. With these lockdown scenarios, and in general, the more dominant influence of the the pre-symptomatic and asymptomatic infectious over the symptomatic infectious, is shown in various ways. Numerical simulations for the U.S. show that an increase in testing and isolating for the pre-symptomatic and asymptomatic infectious group has up to 4 times more impact than an increase in testing for the symptomatic infectious in terms of cumulative deaths. An increase in testing for the pre-symptomatic and asymptomatic infectious group also has significantly more impact (on the order of twice as much) on reducing the control reproduction number than testing for symptomatic infectious. Lastly, we use our model to simulate an implementation of a natural herd immunity strategy for the entire U.S. and for the state of Wisconsin (once an epicenter for COVID-19). These simulations provide specific examples confirming that such a strategy requires a significant number of deaths before immunity is achieved, and as such, this strategy is certainly questionable in terms of success.



    The coronavirus, known as COVID-19, emerged in Wuhan, China in December 2019, and has since then spread to all countries on earth. By 12/10/2020, the United States reported 15,535,565 cases and 291,403 deaths and although the leading country in both deaths and cases, the U.S. did not implement a national pandemic control initiative. Instead, many states and cities implemented their own initiatives at various times, and the transmission of COVID-19 has varied from state to state. States also implemented their own testing initiatives. Around 12-10-2020, the reported testing rates for Wisconsin was 562.4 tests per 100,000 people and for the entire US it was 5372 tests per million [1,2]. With regard to mask usage, the observed mask usage percentage in the US has increased since the beginning of the pandemic. From March 1, 2020 to May 1, 2020, the mask use percentage increased from 5% to 40%. From May 1, 2020 to November 22, 2020, the mask use percentage increased from 71%. Social distancing has also played a role in the transmission of COVID-19. From March 8, 2020 to April 4, 2020, the US experienced a 53% decrease in mobility. From April 4, 2020 to June 24, 2020, the decrease in mobility changed to only -22%. From June 24, 2020 to November 22, 2020, the mobility oscillated between -18% and -25% [3]. The social distancing statistics are due to the fact that different states implemented stay-at-home periods for various intervals of time. All of these factors play a part in the transmission of COVID-19 in the US as a whole, and effectively in each state. Although we do not consider all of these measures directly, our model does include these pertinent features such as mask usage.

    Mathematical modelling can help us better understand how COVID-19 cases and mortality is affected based on when and how long lockdown periods are enforced. Modelling can also help us identify the main drivers of the disease and give insight on how best to use the standard control and mitigation strategies. We expand on the standard SIR model, which uses a system of ordinary differential equations to model disease spread through multiple compartments over time. In this study, we do not consider a time-varying system.

    Prior studies consider susceptible individuals transitioning to exposed and then to being infectious. We include a pre-symptomatic compartment for individuals who are infectious before the onset of symptoms, if any. We also consider individuals who were tested, resulting in an asymptomatic or symptomatic classification, as well as the population of people who may have self-isolated after being exposed by an infected individual. It is known that over the course of the pandemic, hospitals have been highly stressed and over-crowded due to the influx of COVID-19 patients. In order to study mortality due to the pandemic, we also include compartments that keep track of the number of patients admitted to the hospital and the ICU.

    COVID-19 is transmitted by both symptomatic, pre-symptomatic and asymptomatic individuals [4] and most infections show mild or no clinical symptoms [5]. Obtaining real time data separating the two groups is difficult especially since the pre-symptomatic and asymptomatic individuals do not exhibit symptoms and hence have been less likely to be tested and reported; hence, the need for a model. Our study is designed to investigate the role of the symptomatic, pre-symptomatic and asymptomatic more closely using data from the U.S. and the state of Wisconsin which at one time was an epicenter for the COVID-19 pandemic. The research questions are chosen with the aim of analyzing the different aspects of the contribution and effect of asymptomatic and pre-symptomatic transmission versus symptomatic transmission. A better understanding of this transmission is key to developing more informed and effective containment and mitigation strategies for COVID-19 [6] and this information might prove helpful for future coronaviruses and other infectious diseases.

    Our model is similar to the model in [7]; however, unlike our model, [7] splits the symptomatic infectious into both mild and severe symptomatic classes and the recovered into tested and not tested. While [7] does include the pre-symptomatic and asymptomatic classes, the role of these infectious classes is not the focus and a comparison of the roles is not done. More specifically, our work builds on [7] in terms of focusing in more depth (and in various ways) on distinguishing between the contributions of the asymptomatic and pre-symptomatic versus the symptomatic. For example, we include figures that emphasize the contrast in the impact of testing for the two groups and we also align our testing and detection parameters to more so reflect the raw testing rate data.

    Asymptomatic and pre-symptomatic transmission has been considered in other studies, e.g., in terms of the data [5,8] and with an agent-based model [9]. We add to this body of research by considering the role of this silent transmission using a compartmental epidemiological model that is parameterized with mortality data from Wisconsin and the entire U.S. Our model incorporates pertinent aspects of COVID-19 transmission and dynamics and is based on a deterministic system of differential equations. The authors note that the model does not include vaccines since at the time of the development and analysis of the model, vaccines were not yet available, but inclusion of vaccines (and different strains of COVID-19) will be addressed in upcoming work.

    We explore scenarios where lockdown is started earlier or extended past the reported lockdown date. We show that both scenarios decrease the number of cases and deaths. We can use these type of simulations to predict future mortality populations and use the information to help with determining when lockdown periods should start and how long the lockdown period should be enforced. As the main goal is to investigate the contribution of the different infectious classes to the spread of the disease, we consider the effects of lockdown in terms of the two infectious groups.

    Finally, in response to some public discussions of a natural herd immunity approach, we use our model to run some basic scenarios for implementing such a strategy in the state of Wisconsin and the US as a whole. We simulate the number of deaths that would occur before herd immunity is achieved. The goal is to clearly and concretely illustrate the specific high burden of such an approach in terms of our model and data from Wisconsin and the U.S.

    The overall purpose of this study is to compare and contrast the roles of the asymptomatic and pre-symptomatic infectious individuals in the post-lockdown dynamics of COVID-19. Because both the asymptomatic and pre-symptomatic infectious spread COVID-19 without showing symptoms we group these two compartments together and compare that 'silent transmission" group to the symptomatic infectious. More specifically, we use a mathematical model to address the following questions for Wisconsin and the entire US. The section of the paper in which each question is addressed is given after the question.

    ● How do changes in lockdown dates (i.e., earlier or later lockdown dates) affect the number of cases - especially in terms of asymptomatic and pre-symptomatic versus symptomatic - as well as cumulative deaths? (Section 4.3.1)

    ● In general, how does the contribution of the pre-symptomatic and asymptomatic infectious individuals compare to that of the symptomatic infectious in terms of cases and deaths? (Section 4.3.2)

    ● If we isolate all symptomatic infectious individuals or all asymptomatic and pre-symptomatic infectious individuals, how will this impact the number of deaths and cases? (Section 4.3.3)

    ● How might a minimum testing rate for pre-symptomatic and asymptomatic compare to that for the symptomatic infectious individuals in order to obtain a reproduction number below 1? (Section 4.3.4)

    ● How many deaths will occur in a natural herd immunity simulation for Wisconsin and the entire US? (Section 4.4)

    In order to assess and deliver guidelines for individuals to avoid coronavirus infection, the CDC has implemented models equipped with the many stages of the virus [10]. A person who has been infected is considered pre-symptomatic (an individual who is infectious but does not show symptoms at the time of testing) or asymptomatic (a person who is infectious and does not show symptoms throughout the course of the infection). If symptoms set in, the infectious individual is considered symptomatic. The CDC built pandemic planning scenarios varying the infectiousness of asymptomatic individuals compared to symptomatic, varying the percent of asymptomatic individuals, and varying the percentage of transmission of pre-symptomatic individuals. In this paper, we use similar methods to build our model and determine parameter values for the locations and time periods of interest. Figure 1 shows the stages of COVID-19, especially the overlap of the infectious period with the pre-symptomatic period, asymptomatic period and symptomatic period. It should be noted that a pre-symptomatic infectious individual can become either asymptomatic or symptomatic infectious.

    Figure 1.  The Stages of COVID-19. Note that the arrow designating "onset of symptoms" is only for individuals who have symptoms, referring to the symptomatic individuals.

    We are interested in modeling COVID-19 in the United States as a whole, as well as focusing on Wisconsin, since Wisconsin was an epicenter later on in 2020 and is located in the "heartland of America". Table 1 shows some mortality data for Wisconsin and the US.

    Table 1.  This table gives some mortality data for Wisconsin and the United States during several different time periods.
    Cumulative Deaths
    Beginning of lockdown End of lockdown on August 11, 2020 on November 23, 2020
    United States 16767 104803 164519 257779
    Wisconsin 10 594 1006 3158

     | Show Table
    DownLoad: CSV

    We use a modified Kermack-McKendrik-type epidemic (no human demography) model to better understand the dynamics of COVID-19. Since a main objective of this study is to analyze the role of infectious individuals who show no symptoms, the model Figure 2 includes pre-symptomatic and asymptomatic compartments. We use a deterministic susceptible, exposed, pre-symptomatic, symptomatically-infectious, asymptomatically-infectious, self-isolated, hospitalized, recovered, and ICU patients modeling framework, with the classes denoted as S(t), E(t), EP(t), I(t), A(t), J(t), H(t), R(t), C(t) respectively; we also include D(t) to track deaths. The model also includes the mitigation/control interventions of face mask usage (with a compliance parameter as well as a face mask efficacy parameter [7]) and testing/detection implementation for each of the infectious classes.

    Figure 2.  10-compartment flow diagram of the model.

    We obtain the observed cumulative deaths and cases data for the state of Wisconsin and the entire US from the COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (2020). The repository contains data beginning at January 22, 2020 (the marked beginning of the pandemic in the US), however, we focus primarily on the data from March 1, 2020 through October 13, 2020. We fit the parameters using mortality data because it has been found to be more reliable than incidence data [7,11,12]

    The model has 24 parameters and we use values from the literature for 18 of these and estimate the remaining 6 by fitting the model to the observed cumulative mortality data. The parameters that are estimated are as follows: the effective contact rate for the symptomatically-infectious individuals βI, the effective contact rate for the asymptomatically-infectious individuals βA, the effective contact rate for pre-symptomatically-infectious individuals βP, the rate at which presympotomatically-infectious individuals self-isolate τP, the rate at which asympotomatically-infectious individuals self-isolate τA, and the hospitalization rate for self-isolating individuals αJ. Parameter fitting was performed using a standard non-linear least-squares approach - i.e. determining the best parameters set that minimizes the sum of the square of the difference between the model outputs for death and the observed values for deaths.

    Our model for the transmission dynamics of COVID-19 is given by the following deterministic system of non-linear differential equations.

    dSdt=βI(1ϵmcm)SINβA(1ϵmcm)SANβP(1ϵmcm)SEPN=λSdEdt=βI(1ϵmcm)SIN+βA(1ϵmcm)SAN+βP(1ϵmcm)SEPNσeE=λSσeEdEPdt=σeEσpEPτpEPdIdt=rσpEPαIIτIIγIIδIIdAdt=(1r)σpEPαAAτAAγAAδAAdHdt=αII+αAA+αJJψHHγHHδHHdCdt=ψHHγCCδCCdJdt=τpEP+τAA+τIIαJJγJJdRdt=γII+γAA+γCC+γJJ+γHHdDdt=δAA+δII+δHH+δCC (3.1)

    where N(t)=S+E+EP+I+A+H+J+C+R is the total population at time t. The parameter and its description is as follows: ϵm - the efficacy of face masks to prevent transmission and acquisition of infection, cm - the compliance in face mask usage in the community (0<cm1), σ - the progression rate from exposed (E) to infectious classes (I or A), r - the fraction of exposed individuals who show clinical symptoms at the end of the incubation period, τI- the rate self-quarantined symptomatically-infectious humans self-isolate, γI, γA, γJ, γH, γC- the recovery rates for the subscripted population, ψH - the rate of ICU admission for hospitalized individuals, αI- the hospitalization rate for symptomatically-infectious individuals, αA- the hospitalization rate for asymptomatically-infectious individuals, δI, δA, δH, δC -the disease-induced mortality rates for the subscripted population. We assume that hospitalized individuals do not come in contact with the general population.

    The state variables, the parameters for our model and the mask compliance parameters are given in Tables 2, 3, and 4 respectively.

    Table 2.  State variables description.
    State Variable Description
    S Population of susceptible individuals
    E Population of non-quarantined exposed individuals (infected but not showing symptoms and cannot transmit infection; newly-infected but not infectious)
    EP Population of pre-symptomatic (infectious) individuals
    I Population of symptomatically-infectious individuals
    A Population of asymptomatically-infectious individuals
    J Population of self-isolated individuals
    H Population of hospitalized individuals
    R Population of recovered individuals
    C Population of individuals in intensive care unit (ICU)
    D Population of COVID-19 deceased individuals

     | Show Table
    DownLoad: CSV
    Table 3.  Parameter notation, description, values and sources for the model in section 3.1. Some values change depending on the time period and for simulations that are post post-lockdown or involve testing implications, the testing parameter values are chosen to more-so align with reported testing trends.
    Parameter Description Range Baseline value References
    βI Effective contact rate for symptomatically-infectious individuals Fitting Fitting Fitting
    βA Effective contact rate for asymptomatically-infectious individuals Fitting Fitting Fitting
    βP Effective contact rate for pre-symptomatically-infections individuals Fitting Fitting Fitting
    ϵm Efficacy of face masks to prevent transmission and acquisition of infection (0<ϵm1) 0.4 –0.6 0.5 [7]
    cm Compliance in face mask usage in the community (0<cm1) 0.0190-0.1835 per state [7]
    σe Progression rate from exposed (E) to pre-symptomatic infectious class (EP) infectious class 1/2.5 day1 1/2.5 day1 [7]
    σP Progression rate from pre-symptomatic infectious class (EP) to asymptomatically infectious or symptomatically infectious 1/2.5 day1 1/2.5 day1 [7]
    r Fraction of exposed individuals who show clinical symptoms at the end of the incubation period 0.4 – 0.6 0.6 [13,14,15]
    τP Rate at which pre-symptomatic infectious individuals self-isolate Fitting Fitting Fitting
    τI Rate self-quarantined symptomatically-infectious humans self-isolate 0.07 - 0.4681 day1 1/2.5 day1 [16,17,18,19,20,21]
    τA Rate at which asymptomatically-infectious humans self-isolate Fitting Fitting Fitting
    γI Recovery rate for individuals in the I class 1/30 – 1/3 day1 1/7 day1 [13,14,15]
    γA Recovery rate for individuals in the A class 1/14 – 1/3 day1 1/7 day1 [13,14,15]
    γJ Recovery rate for self-isolated individuals 0.0714 – 0.1667 day1 1/8 day1 [13]
    γH Recovery rate for hospitalized patients 1/30 – 1/3 day1 1/14 day1 [13,14,15]
    γC Recovery rate for ICU patients 0.018 – 0.14 day1 0.0225 day1 [13,22]
    ψH Rate of ICU admission for hospitalized individuals 0.02 – 0.1667 day1 0.083 day1 [13,15,21]
    αI Hospitalization rate for symptomatically-infectious individuals 0.1111 - 0.3333 day1 0.2199 day1 [14,15,23]
    αA Hospitalization rate for asymptomatically-infectious individuals 0.1667 – 0.3333 day1 1/4 day1 [13,24,25]
    αJ Hospitalization rate for self-isolated individuals Fitting Fitting Fitting
    δI Disease-induced mortality rate for symptomatically-infectious individuals 0.001 – 0.1 day1 0.0225 day1 [13,15,21,26]
    δA Disease-induced mortality rate for asymptomatically-infectious individuals 0.001 – 0.1 day1 0.0075 day1 [15,26]
    δH Disease-induced mortality rate for hospitalized individuals 0.001 – 0.1 day1 0.015 day1 [14,15,21]
    δC Disease-induced mortality rate individuals in ICU 0.001 – 0.1 day1 0.0225 day1 [14,15,26]

     | Show Table
    DownLoad: CSV
    Table 4.  The mask compliance rates during the respective periods.
    Mask compliance level cm
    Pre-lockdown Lockdown Post-lockdown
    United States 0.0278 0.1835 0.1835
    Wisconsin 0.0278 0.1835 0.1392

     | Show Table
    DownLoad: CSV

    The basic reproduction number R0 is the average number of secondary infections produced when one infected individual is introduced into a host population of susceptible individuals. For our model's R0, we have R0=R0A+R0I+R0P where R0A, R0I, R0P, correspond to the subscripted populations with

    R0A=βA(1r)αA+γA+δA
    R0I=βIrαI+γI+δI

    and

    R0P=βPσP.

    Note that 1αA+γA+δA is the mean infectious duration in the asymptomatic infectious class; so that the R0A is that number times the product the proportion of exposed individuals that move to the asymptomatic class - 1r and the asymptomatic effective contact rate - βA. Similar explanations hold for R0I and R0P.

    The control reproduction number RC is the average number of new cases generated by a typical infectious individual introduced into a host population of susceptible individuals with some control measures/interventions in place. Using the next generation operator method and notation found in [27] we have the following computation for the control reproduction number RC. If we take the column vector [EEPIA] representing the compartments of infected, then the associated next generation matrices, F and V, for the new infection terms and the transition terms are given respectively as

    F=[0(1ϵmcm)βP(1ϵmcm)βI(1ϵmcm)βA000000000000]andV=[σe000σeG1000rσPG200(1r)σP0G3]

    where, G1=σP+τP, G2=αI+γI+δI+τI, G3=αA+γA+δA+τA. Thus, RC is the spectral radius of the next generation matrix given by,

    RC=ρ(FV1)=RI+RA+RP

    where RI=(1ϵmcm)βIrσPG1G2, RA=(1ϵmcm)(1r)βAσPG1G3, and RP=(1ϵmcm)βPG1. In absence of interventions, i.e. with τI=τA=τP=τA=ϵm=cm=0, we get the basic reproduction number R0, as given earlier.

    The model has a family of disease-free equilibrium given by: (S,E,Ep,I,A,H,C,J,R)=(S(0),0,0,0,0,0,0,0,0), where S(0) is the initial number of susceptible individuals in the population and we obtain the following result.

    Theorem 1.

    The disease-free equilibrium (DFE) of the model is locally-asymptotically stable if RC<1. If RC>1, the epidemic rises and then eventually declines to zero.

    A basic implication of Theorem 1 is that in order to control the COVID-19 outbreak (to not generate more), it suffices to keep RC<1. For epidemic models, (i.e., models without birth and death processes, such as the one that we have), this is a sufficient but not a necessary condition; that is, the disease will eventually die out (in the limit). For models with birth and death processes, this will be a necessary condition.

    We can also plot a reproduction number that varies with time; it is called the effective reproduction number [29]. The effective reproduction number is given as Rc(t)=(R0)(S(t)N(t) where S(t) is the susceptible at time t, N(t)=S+E+EP+I+A+H+J+C+R is the total population at time t and R0 is the basic reproduction number. Figure 3 illustrates the typical behavior of Rc(t) using our model and data for the U.S.

    Figure 3.  Time varying reproduction number Rc(t) for the U.S.

    We measured how well each model fit the data using the T-Test function "t.test" in R. The T-Test measures the difference between two sets of continuous data by comparing two sample means to determine if there is a statistically significant difference between a given model and data. We used a paired T-Test where each vector had the same amount of entries and the values were taken from the same independent variable. We assumed that the data in each vector was normally distributed and that they had approximately equal variances. To test for normality, we used the Shapiro-Wilk Test function "shapiro.test" in R. Let H0, the null hypothesis, be normally distributed values in the vector. We visualize this using the Q-Q plots in Appendix A, where we assume normality if all the points fall along the reference line. After verifying that the data points are indeed normally distributed, let the null hypothesis for the T-Test be that the difference between the two groups is 0. The T-statistic is defined as

    T=¯x1¯x2(s21/n1)+(s22/n2),

    where, ¯x1 is the mean of the data, ¯xs is the mean of the model values, s21 is the variance of the data, s22 is the variance of the model values, n1 is the sample size of the data, and n2 is the sample size of the model values. We conclude that the model for Wisconsin during the lockdown period does indeed fit the data. It is important to note that the results of the T-Test for the United States leads us to believe that the model does not fit the data. However, this is due to the size of the population (the cost of large numbers) in this curve. We say that the model for the US fits the data by eye. Table 5 shows the resulting p-values of the T-Test for Wisconsin and the United States during the lockdown period. The goodness of fit plots can be found in the Appendix (section 6.3) in Figures 16 and 17.

    Table 5.  The results of the T-Test for the daily and cumulative curves from the beginning of the lockdown period until the end of the lockdown period. The daily column denotes the model vs the data of the daily deaths. The cumulative column denotes the model vs the data of the cumulative deaths.
    State Conclusion Daily p-value Cumulative p-value
    United States Different Mean 0.9827 0.1633
    Wisconsin Same Mean 0.0235 2.2e-16

     | Show Table
    DownLoad: CSV

    We can measure the impact of the sensitivities of the parameters with respect to the control reproduction number. Figure 4 gives sensitivity analysis in terms of the partial rank correlation coefficients (PRCCs) for the parameters [28,29]. This figure indicates that the parameters that have the most effect on the control reproduction number are the effective contact rate for the pre-symptomatic infectious individuals (βP), the effective contact rate for the asymptomatic infectious individuals (βA) and the testing/isolation rate for the pre-symptomatic infectious individuals (τP). This result is consistent with our findings that the pre-symptomatic and asymptomatic individuals are the main drivers of the COVID-19 pandemic.

    Figure 4.  Partial rank correlation coefficients indicating the impact of parameter values on the control reproduction number.

    We fit our model using the cumulative and daily mortality data for Wisconsin and the entire US over the pre-lockdown, lockdown, and post-lockdown periods based on the respective decisions. Wisconsin and the US pre-lockdown period is defined from March 19, 2020 to March 25, 2020 and March 1, 2020 to April 7, 2020 respectively. The lockdown period is defined from March 25, 2020 to May 26, 2020 and April 7, 2020 to May 28, 2020 respectively. For the post-lockdown, we primarily use the dates May 26 to August 11, 2020 and May 28, 2020 to August 11, 2020, respectively [7]. Figure 5 shows the fit for our model with the cumulative deaths data during the pre-lockdown, lockdown and post-lockdown periods.

    Figure 5.  Data fitting of the model for pre-lockdown (A, D), lockdown (B, E) and post-lockdown (C, F), using COVID-19 mortality data for Wisconsin and the US. The plots show the model (blue line) against the data (red dotted line).

    In this section about lockdown we do the following: (1) illustrate the effects of earlier lockdowns on the number of cases of asymptomatic and pre-symptomatic versus symptomatic, (2) show the benefit of lockdown extensions for the state of Wisconsin, and (3) give simulations of how lockdown might have helped during/before the winter holiday period.

    The first lockdown was implemented in the month of March. Since an earlier lockdown would have most likely prevented the disease from gaining a foothold in these areas, an earlier lockdown reduces the number of cumulative deaths. In general, an earlier lockdown also results in a decrease in daily cases for both the symptomatic and asymptomatic/pre-symptomatic compartments, and moreover, during these earlier lockdowns, the asymptomatic and pre-symptomatic dominate by a factor of at least 2, as shown in the daily cases plots for the entire US in Figure 6. A decrease occurs each time we add one week to the beginning of the lockdown period, e.g., the maximum daily cases for the pre-symptomatic and asymptomatic goes from about 16,000 (Fig 6A) to 6000 (Fig 6B).

    Figure 6.  Daily cases for the asymptomatic/pre-symptomatic individuals (cyan curve) versus the symptomatic individuals (red curve) for the entire US, if (A) lockdown began 1 week earlier on March 31, 2020 and if (B) lockdown began 2 weeks earlier on March 24, 2020.

    A different scenario involves extending lockdown. If for Wisconsin, we use the original lockdown start dates but extend the lockdown periods by 2 and 4 weeks - Figure(7), we see a decrease in cumulative deaths of about a 14% at the end under a 4 week extension, as shown in Figure 7B.

    Figure 7.  The cumulative deaths for Wisconsin if (A) lockdown was lifted 2 weeks later ending on June 9, 2020 and if (B) lockdown was lifted 4 weeks later ending on June 23, 2020.

    These varying lockdown dates scenarios can be used to assess the efficacy of lockdown periods and to guide the manner in which the lockdown periods are implemented. For example, one other interesting lockdown scenario is to consider what would happen if the entire U.S. and Wisconsin implemented a lockdown during the month of December 2020 for two weeks. In order to simulate such a strategy we reduce the contact rate parameters - i.e., the betas - by 40% [21] and run the simulations forward. As depicted in Figure 8 below, the simulations give that such a lockdown would result in a marked decrease in the number of deaths - around 10% decrease for the U.S. (Fig 8A).

    Figure 8.  Cumulative deaths in (A) the U.S. and (B) Wisconsin. The green line represents lockdown implementation in December, the blue line represents no lockdown implementation, and the red line represents the data from John Hopkins.

    We now focus more on comparing the contributions of the symptomatic infectious group with the asymptomatic and pre-symptomatic infectious group. First, we consider plotting the daily cases for the two groups against each other during the postlockdown period ending on 8/11/2020. In both the state of Wisconsin and the entire U.S., we find that the number of daily cases for the asymptomatic and pre-symptomatic is at least twice more than the daily cases for the symptomatic - Figure 9. We can also focus on each group separately. The parameter βI represents the contacts by the symptomatically infectious individuals that could transmit the disease. By setting βI=0, we eliminate that transmission and focus on the effect of the pre-symptomatic and asymptomatic individuals. Similarly, fixing βA=βP=0, targets the effect of the symptomatically infectious. In order to further discern the role of the asymptomatic and pre-symptomatic infectious versus that of the symptomatic infectious, we consider these zero contact rate scenarios, in terms of the number of daily cases Wisconsin and the entire US. In Figure 10, we show these results for post-lockdown periods and we again get that the larger contribution comes from the asymptomatic and pre-symptomatic individuals.

    Figure 9.  The plots show the daily cases for pre-symptomatic and asymptomatic versus symptomatic for (A) the Wisconsin post-lockdown period from May 26, 2020 to August 11, 2020 and (B) the U.S. post-lockdown period from May 28, 2020 to August 11, 2020.
    Figure 10.  The plots show the daily cases with βI=0 (The cyan curve focuses on the impact of asymptomatic/pre-symptomatic individuals) and with βA=βP=0 (The red curve focuses on the impact of symptomatic individuals) during (A) the Wisconsin post-lockdown period from May 26, 2020 to August 11, 2020, and (B) the U.S. post-lockdown period from May 28, 2020 to August 11, 2020.

    In Figure 11, we again plot the βI=0 (green curve) versus the βA=βP=0 (magenta curve) scenario, but here we consider the effect in terms of cumulative cases and cumulative deaths. The solid blue curve corresponds to the model using baseline β values. Both types of plots depict that the main drivers are the asymptomatic and pre-symptomatic individuals and for cumulative deaths the difference is around a factor of 1.3.

    Figure 11.  The cumulative cases (A, C) and cumulative deaths (B, D) over the respective post-lockdown periods where Case 1 corresponds to βI=0 (The green curve focuses on the impact of asymptomatic/pre-symptomatic individuals). Case 2 corresponds to βA=βP=0 (The magenta curve focuses on the impact of symptomatic individuals).

    Recall that the τ values give the rate for testing/detection of infected individuals and subsequent self-isolation. In this section we compare and contrast the effect of isolating the symptomatic against the effect of isolating the asymptomatic and pre-symptomatic by changing the appropriate τ values. For example, to address the effect of isolating symptomatic infectious individuals, we can increase the value of τI (the rate that symptomatically infectious individuals self-isolate) while keeping all other rates the same. We consider this scenario for the entire US and find that when τI increases (so that the number of symptomatically infectious individuals that are self-isolated and taken out of the general population increases), the number of cumulative deaths decreases by as much as 12.5% (Fig 12A). Alternatively, if the rate of self-isolation for the asymptomatic and pre-symptomatic infectious individuals - τA and τP respectively - are increased and the τI is kept at the baseline value for the US, the number of cumulative deaths decreases by about 30% at the end of the period - see Figure 12B. Thus, the decrease is more pronounced (around twice as much) when the τA and τP are increased than when the τI is increased which indicates that the asymptomatic and pre-symptomatic have more impact. Figure 13A focuses on the difference in impact of a 50% increase in testing and shows that the asymptomatic and pre-symptomatic testing gives up to about four times as much percent decrease in deaths as that of the symptomatic. We find that a 50% increase in τA and τP, results in roughly a 20% decrease in cumulative deaths for Wisconsin (Fig 13B). Note that all of the results confirm the greater influence of the asymptomatic and pre-symptomatic infectious.

    Figure 12.  The effect of an increase in testing of symptomatic individuals versus asymptomatic and pre-symptomatic individuals on the cumulative deaths in the US during the post-lockdown period from May 28, 2020 to August 11, 2020. In both plots, the red dotted line represents the data, the blue line represents a 50% increase, the green line represents a 100% increase, and the cyan line represents a 200% increase. (A) The plot describes the increase in τI, symptomatic individuals. (B) The plot describes the increase in τA and τP, asymptomatic and pre-symptomatic individuals.
    Figure 13.  The effect of a 50% increase in testing of asymptomatic and pre-symptomatic versus symptomatic on the cumulative deaths. In both scenarios, the red dotted line represents the data, the green dot-dashed line represents the model of the cumulative deaths by increasing τA and τp (asymptomatic and pre-symptomatic individuals) by 50%, and the purple dashed line represents the model of the cumulative deaths by increasing τI (symptomatic individuals) by 50%. (A) The US post-lockdown period from May 28, 2020 to August 11, 2020. (B) The Wisconsin post-lockdown period from May 26, 2020 to August 11, 2020.

    A key part of controlling COVID-19 involves controlling the reproduction number. With this in mind, we consider the question concerning the minimum rate of testing/detection required to lower the control reproduction number, RC below one. This question is more difficult to answer directly, but we can begin to get at an answer by again considering the effect of increasing testing. For example, for the entire US from May 28 to Aug 11 (after lifting of lockdown) if the testing rate for asymptomatic and pre-symptomatic is 0.2 - that is, if τA and τP are both set to 0.2, while τI=0.4, then the reproduction control number RC is 1.0346 (so just above 1). If τA and τP are bumped above 0.2, for example to 0.25, while τI remains at 0.4, then RC falls below 1 - to 0.95178 - and the resulting decrease in cumulative death (Fig 14A) and daily cases (Fig 14B) is given in Figure 14. To get a better appreciation of the impact of testing for asymptomatic and pre-symptomatic cases, note that if τA and τP are kept at their baseline fitted values, then τI must be increased to 1.7 (from a baseline value of 0.4) to get RC=0.9945. Of course, the challenge with all of these testing scenarios is that the testing of asymptomatic and pre-symptomatic individuals is more difficult since those individuals do not have symptoms, so in order to achieve these testing rates, widespread and frequent testing should be implemented.

    Figure 14.  The effect of an increase in τA and τP (asymptomatic and pre-symptomatic individuals) during the post-lockdown period (May 28, 2020 to August 11, 2020) in the US. (A) The red dotted line represents the data from John Hopkins. The green line represents the model of the cumulative deaths given τA=τP=0.25. (B) The blue line represents the model of the daily cases given τA=τP=0.2. The green line represents the model of the daily cases given τA=τP=0.25.

    At one point in 2020, as the U.S. and world leaders grappled with the pandemic, the idea of a natural herd immunity approach was widely discusses and even endorsed. Using out model and the data for Wisconsin and the U.S., we provide specific simulations that show that a natural herd immunity approach would cost many lives and as such is, at the very least, a rather dubious approach. Natural herd immunity refers to the process by which enough of the population achieves immunity via natural recovery from the disease, so that the remaining population that is not immune also receives protection against the acquisition of the disease. The process involves a natural herd immunity threshold, that is, the minimum number of people required to achieve disease-acquired immunity. For a disease with a basic reproduction number of R0, the necessary minimum fraction of people who must achieve immunity can be given as 11/R0. We simulate for both Wisconsin (a state which was considered an epicenter later in 2020) and the entire US, a scenario in which COVID-19 is allowed to run its natural course (with no implementation of any new control or mitigation strategies) until natural herd immunity is achieved. For both Wisconsin and the entire US, the number of deaths that occur before reaching the herd immunity threshold, is considerably high. For the state of Wisconsin, the number of deaths that occurs is approximately 80,000 (Fig 15A) and for the entire U.S., the number of deaths is more than 5 million (Figure 15B).

    Figure 15.  The number of deaths that will occur before the natural herd immunity threshold is achieved (A) Wisconsin simulations from October 13, 2020 to December 5, 2020. (B) The US simulations from October 13, 2020 to February 26, 2021.

    From various perspectives, our analysis indicates that overall, the drivers of COVID-19 are the asymptomatic and pre-symptomatic infectious individuals, i.e., the silent transmission. Even with vaccines, it is critical to control the spread especially as more and more mutations arise, so gaining a better understanding of containment and mitigation strategies remains key for dealing with COVID-19. Our work emphasizes that these strategies must consider the silent transmission. In particular, the respective answers to the research questions posed in Section 2 are as follows: (1) Our simulations show that even under lockdown, the asymptomatic and pre-symptomatic infectious drive the spread. And although lockdown might be difficult in terms of economic impact, the benefit of even a short lockdown (two weeks) in reducing deaths is considerable - around a 10% decrease for the U.S. in the December 2020 simulations (2) More cases are due to asymptomatic and pre-symptomatic infectious than the symptomatic infectious and the daily cases due to the silent transmission is at least twice the number of symptomatic infectious daily cases. If the effective contact rate for the symptomatic infectious is set to zero (so that the focus is on the silent spread), then the asymptomatic and pre-symptomatic cumulative cases are more than five times that of the symptomatic infectious and asymptomatic and pre-symptomatic individuals account for more than 1.3 times as many of the cumulative deaths. (3) We see that an increase in testing for the asymptomatic and pre-symptomatic infectious has a greater impact than the symptomatic infectious and that (4) to lower the control reproduction number below 1, requires a significantly greater increase in testing/isolating of symptomatic infectious than for asymptomatic and pre-symptomatic. Lastly, (5) we provide two simulations to illustrate and emphasize that a notion of natural herd immunity approach with COVID-19 extracts a heavy burden due to the high number of deaths required to achieve the herd immunity threshold.

    For policy makers, our results show that the dominant role of the asymptomatic and pre-symptomatic in terms of the number of cases and deaths and the testing impact, implies that consideration of this silent transmission is key to controlling the spread of the disease. This is especially true after holiday periods and large gathering events which are often notorious for reduced and lax implementation of control and mitigation strategies such as social distancing and mask usage. Thus, in the schools and workplaces, testing should be intentionally and systematically increased after such occurrences in order to control the silent transmission by the newly infectious individuals who do not (yet) have symptoms. Perhaps this work provides some support for the development of home administered testing. Our simulations also show that although lockdown might be difficult in terms of economic impact, the benefit of even a short (perhaps limited or partial) lockdown in reducing deaths and cases is significant enough to justify the option at least during high risk situations. In particular, the asymptomatic and pre-symptomatic infectious must be definitively accounted for as policy makers move forward.

    The authors extend special thanks to the 2020 African Diaspora Joint Mathematics Workshop (ADJOINT), Dr. Abba Gumel (our ADJOINT group leader) and the Mathematical Sciences Research Institute (MSRI) - especially the MSRI IT members Aaron Hale & Nate Orange. We also acknowledge the following funding sources for ADJOINT: Alfred P. Sloan Foundation (G-2020-12602), National Science Foundation (DMS-1915954 and DMS-2016406), and National Security Agency (H98230-20-1-0015). Kamal Barley acknowledges partial support by National Institutes of Health/NIGMS Award K12GM102778.

    The authors declare no conflicts of interest.

    Goodness of Fit

    In this section, we show the plots for the goodness of fit of the lockdown period for the US and Wisconsin. We also display the boxplot of the values for each set in order to show the mean of the different sets of values.

    Figure 16.  US Row 1: Q-Q plots for the (1) Daily death values from the model (2) Daily death values from the data (3) Cumulative death values from the model (4) Cumulative death values from the data. Row 2: Box plot of the (1) Daily death values from the model and data (2) Cumulative death values from the model and data.
    Figure 17.  Wisconsin Row 1: Q-Q plots for the (1) Daily death values from the model (2) Daily death values from the data (3) Cumulative death values from the model (4) Cumulative death values from the data. Row 2: Box plot of the (1) Daily death values from the model and data (2) Cumulative death values from the model and data.


    [1] COVID-19 Dashboard by the Center for Systems Science and Engineering, 2020. Available from: https://coronavirus.jhu.edu/map.html.
    [2] H. Ritchie, E. Ortiz-Ospina, D. Beltekian, E. Mathieu, J. Hasell, B.Macdonald, et al., Coronavirus Pandemic (COVID-19), Our World in Data, (2020), Available from: https://ourworldindata.org/coronavirus.
    [3] COVID-19 Statistics, 2020. Available from: https://covid19.healthdata.org/united-states-of-america?view=mask-use&tab=trendl.
    [4] Y. Bai, L. S. Yao, T. Wei, F. Tian, D. Y. Jin, L. J. Chen, et al., Presumed asymptomatic carrier transmission of COVID-19, JAMA, 2020.
    [5] World Health Organization, Coronavirus disease 2019 (COVID-19): Situation report, 46, WHO, 2020.
    [6] C. Savvides, R. Siegel, Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review, preprint, arXiv: PMID32587980.
    [7] C. N. Ngonghala, E. A. Iboi, A. B. Gumel, Could masks curtail the post-lockdown resurgence of COVID-19 in the US?, Math. Biosci., 329 (2020), 1–18.
    [8] L. C. Tindale, J. E. Stockdale, M. Coombe, E. S. Garlock, W. Y. Venus Lau, M. Saraswat, et al., Evidence for transmission of COVID-19 prior to symptom onset, eLife, 09 (2020).
    [9] S. M. Moghadas, M.C. Fitzpatrick, P. Sah, A. Pandey, A. Shoukat, B.H. Singer, et al., The implications of silent transmission for the control of COVID-19 outbreaks PNAS, 2020.
    [10] Coronavirus, 2020. Available from: https://www.cdc.gov/coronavirus/2019-84ncov/hcp/planning-scenarios.html.
    [11] H. Lau, T. Khosrawipour, P. Kocbach, H. Ichii, J. Bania, V. Khosrawipour, Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters, Pulmonology, (2020).
    [12] L. H. Sun, J. Achenbach, CDC chief says coronavirus cases may be 10 times higher than reported, The Washington Post (Health), (July 3, 2020).
    [13] C. N. Ngonghala, E. Iboi, S. Eikenberry, M. Scotch, C. R. MacIntyre, M. H. Bonds, et al., Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus, Math. Biosci., 325 (2020).
    [14] A. Gumel, E. Iboi, C. Ngonghala, Using Mathematics to Understand COVID-19 Dynamics, preprint submitted to Notic. of the Am. Math. Soc., (2020).
    [15] S. Eikenberry, M. Mancuso, E. Iboi, T. Phan, K. Eikenberry, Y. Kuang, et al., To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic, Infect. Dis. Model., 5 (2020), 293–308.
    [16] L. Worden, R. Wannier, S. Blumberg, A. Ge, G. Rutherford, T. Porco, Estimation of effects of contact tracing and mask adoption on COVID-19 transmission in San Francisco: a modeling study, preprint, arXiv: PMID32577672.
    [17] G. Chowell, D. Chowell, K. Roosa, R. Dhillon, D. Srikrishna, Sustainable social distancing through facemask use and testing during the Covid-19 pandemic, preprint, arXiv: medRxiv 2020.04.01.20049981.
    [18] T. P. Sheahan, A. C. Sims, S. Zhou, R. L. Graham, A. J. Pruijissers, M. L. Agostini, et al., An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice, Sci. Transl. Med., 12 (2020).
    [19] A. J. Kucharski, P. Klepac, A. J. K. Conlan, S. M. Kissler, M. L. Tang, H. Fry, et al., Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study, Lancet Infect. Dis., 20 (2020), 1151–1160. doi: 10.1016/S1473-3099(20)30457-6
    [20] S. Tian, Z. Chang, Y. Wang, M. Wu, W. Zhang, G. Zhou, et al., Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China, Front. in Med., 7 (2020).
    [21] E. A. Iboi, C. N. Ngonghala, A. B. Gumel, Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.? Infect. Dis. Model., 5 (2020), 510–524.
    [22] J. Gold, K. K. Wong, C. M. Szablewski, P. R. Patel, J. Rossow, J. da Silva, et al., Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 -Georgia, March 2020, Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, 69 (2020), 545–550. doi: 10.15585/mmwr.mm6918e1
    [23] S. Garg, L. Kim, M. Whitaker, A. O'Halloran, C. Cummings, R. Holstein, et al., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1 - 30, 2020, Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, 69 (2020), 458–464. doi: 10.15585/mmwr.mm6915e3
    [24] Management of Patients with Confirmed 2019-nCoV, 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
    [25] Y. Wang, D. Zhang, G. Du, R. Du, J. Zhao, Y. Jin, et al., Remdesivir in adult with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, The Lancet, 395 (2020), 1569–1578. doi: 10.1016/S0140-6736(20)31022-9
    [26] N. M. Ferguson, D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, et al., Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand, Imp. Coll. Lon., 2020.
    [27] P. Van den Driessche, J. Watmough, Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180 (2002), 29–48.. doi: 10.1016/S0025-5564(02)00108-6
    [28] S. Marino, I. Hogue, C. Ray, D. Kirschner, A Methodology For Performing Global Uncertainty and Sensitivity Analysis in Systems Biology, J. Theor. Biol., 254 (2008), 178–196. doi: 10.1016/j.jtbi.2008.04.011
    [29] A. Gumel, E. Iboi, C. Ngonghala, E. Elbasha, A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations, Infect. Dis. Model., 6 (2021), 148–168.
  • Reader Comments
  • © 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(3247) PDF downloads(140) Cited by(0)

Figures and Tables

Figures(17)  /  Tables(5)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog